Atlas Trials

B-cell Malignancy

17 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch B-cell Malignancy

RecordFirmDate
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (NCT05294731)BeiGene2022-05-06
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma (NCT05106946)Fundamenta Therapeutics, Ltd.2021-10-25
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma (NCT05106907)Fundamenta Therapeutics, Ltd.2021-10-25
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (NCT05006716)BeOne Medicines2021-09-13
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies (NCT04601181)Fundamenta Therapeutics, Ltd.2020-10-23
Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies (NCT04384393)Fundamenta Therapeutics, Ltd.2020-05-09
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) (NCT04035434)CRISPR Therapeutics AG2019-07-22
CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients (NCT03953599)Hebei Yanda Ludaopei Hospital2019-07-01
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies (NCT03559439)Shanghai Tong Ren Hospital2018-04-24

Track B-cell Malignancy automatically

Every clearance here is in the API, with alerts when new ones post.